function confirmModerate(url,num,pid){ url = url + '?Comments[do]=mod&Comments[pid]=' + pid + '&Comments[id]=' + num + '#Comments_' + num; if (confirm('Do you want to report this comment as inappropriate?')) location.href=url; return 0; } function validate_form(frm) { var value = ''; var errFlag = new Array(); _qfMsg = ''; value = frm.elements['Comments[name]'].value; if (value == '' && !errFlag['name']) { errFlag['name'] = true; _qfMsg = _qfMsg + '\n - Please enter your name'; } value = frm.elements['Comments[captcha]'].value; if (value == '' && !errFlag['captcha']) { errFlag['captcha'] = true; _qfMsg = _qfMsg + '\n - Please enter Security Code'; } value = frm.elements['Comments[mail]'].value; if (value == '' && !errFlag['mail']) { errFlag['mail'] = true; _qfMsg = _qfMsg + '\n - Please enter your e-mail'; } var regex = /^((\"[^\"\f\n\r\t\v\b]+\")|([\w\!\#\$\%\&'\*\+\-\~\/\^\`\|\{\}]+(\.[\w\!\#\$\%\&'\*\+\-\~\/\^\`\|\{\}]+)*))@((\[(((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9])))\])|(((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9])))|((([A-Za-z0-9\-])+\.)+[A-Za-z\-]+))$/; if (value != '' &&!regex.test(value) && !errFlag['mail']) { errFlag['mail'] = true; _qfMsg = _qfMsg + '\n - E-mail address format is invalid'; } value = frm.elements['Comments[text]'].value; if (value == '' && !errFlag['text']) { errFlag['text'] = true; _qfMsg = _qfMsg + '\n - Please enter your comment'; } if (value.length<50 && !errFlag['text']) { errFlag['text'] = true; _qfMsg = _qfMsg + '\n - Comment is too short (50 characters min.)'; } if (value.length>4000 && !errFlag['text']) { errFlag['text'] = true; _qfMsg = _qfMsg + '\n - Comment is too long (4000 characters max)'; } if (_qfMsg != '') { _qfMsg = 'Invalid information entered:' + _qfMsg + '\nPlease correct these fields.'; alert(_qfMsg); return false; } return true; } //]]>

Parting shot

Article Abstract:

A new oral drug, Troglitazone with the brand name Razulin, is being approved by the FDA for use by a limited number of type II diabetics. This group of diabetics do not respond well to insulin injections. In studies, some of the people were able to stop taking insulin.

Publisher: Rodale, Inc.
Publication Name: Prevention
Subject: Sports and fitness
ISSN: 0032-8006
Year: 1997

Care and treatment, Usage, Complications and side effects, Type 2 diabetes, Rezulin (Medication), Insulin, Troglitazone

User Contributions:

Comment about this article or add new information about this topic:

Long-time partners to carry Toyota banner in 1997 Indy Car competition

Article Abstract:

Toyota is participating in the PPG CART World Series for the second year in 1997 by supplying the All American Racers and Arciero-Wells teams with V8 Indy car engines. Juan Manuel Fangio, II; PJ Jones; Max Papis; and Hiro Matsushita will be the drivers.

Publisher: Time, Inc.
Publication Name: Field & Stream (West ed.)
Subject: Sports and fitness
ISSN: 8755-8610
Year: 1997

Contracts, Automobile industry, Competitions, Toyota Motor Sales U.S.A. Inc., Automobile racing, Championship Auto Racing Teams

User Contributions:

Comment about this article or add new information about this topic:

Similar abstracts:

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.